Key Points
- Insider sale: Salvatore Privitera sold 7,763 AtriCure shares at $52.50 each for approximately $407,558 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 4.89%.
- Financial performance: AtriCure reported quarterly revenue of $153.6 million, above analyst estimates of $151.8 million, and earnings of $0.18 per share versus a loss of $0.13 per share a year earlier.
- Analyst sentiment: Recent brokerages raised several price targets, including Needham’s increase to $64 and Piper Sandler’s to $60. The stock carries a “Moderate Buy” consensus rating with an average target of $52.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Salvatore Privitera sold 7,763 shares of AtriCure stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the sale, the insider directly owned 150,921 shares of the company's stock, valued at $7,923,352.50. This trade represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AtriCure Trading Down 1.8%
NASDAQ ATRC opened at $51.52 on Friday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $53.50. The firm's fifty day simple moving average is $40.10 and its 200-day simple moving average is $32.83. The company has a market capitalization of $2.62 billion, a PE ratio of 245.35 and a beta of 1.26.
AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on ATRC. BTIG Research raised their price objective on shares of AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, August 24th. Piper Sandler boosted their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. UBS Group dropped their price target on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Needham & Company LLC lifted their price objective on shares of AtriCure from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Citigroup reiterated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, AtriCure presently has a consensus rating of "Moderate Buy" and an average price target of $52.00.
Read Our Latest Report on ATRC
Institutional Trading of AtriCure
Large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new stake in shares of AtriCure in the second quarter valued at about $37,000. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure in the 2nd quarter worth approximately $40,000. Allworth Financial LP bought a new stake in AtriCure during the 2nd quarter worth approximately $43,000. Smartleaf Asset Management LLC grew its holdings in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of AtriCure in the first quarter valued at approximately $51,000. 99.11% of the stock is owned by institutional investors.
About AtriCure
(
Get Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
